Posted by Michael Wonder on 05 Aug 2015
Process changes for end of life and very rare conditions
6 May 2014 -
The Scottish Medicines Consortium has been asked to apply more flexible approaches to the evaluation of medicines used at the end of life and for very rare conditions. The new processes include the option of a Patient and Clinican Engagement (PACE) group. This will give patient groups and clinicians a stronger voice in SMC decision making. In addition, the assessment process for ultra-orphan medicines will involve a broad decision-making framework.
For more details, go to: http://www.scottishmedicines.org.uk/files/new_medicines_review/PACE_Overview_Document_May_2014.pdf
Posted by:
Michael Wonder
Posted in:
